What is the price of Artiva Biotherapeutics, Inc. (ARTV)

The price of Artiva Biotherapeutics, Inc. (ARTV) is $11.09

What is the market cap of Artiva Biotherapeutics, Inc. (ARTV)

The market cap of Artiva Biotherapeutics, Inc. (ARTV) is $542.19M

Artiva Biotherapeutics, Inc. (ARTV) Price History

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.

Year	Performance
2026 (TTM)	59.60%
2025	-64.18%
2024	0.00%

Year

Performance

2026 (TTM)

59.60%

2025

-64.18%

2024

0.00%

Company	Stock price	Change 1y%	Country
Vertex Pharmaceuticals Incorporated VRTX.US	$542.09	38.63%	US
Argenx SE ARGX.US	$1.03K	44.13%	NL
CSL Limited CSL.AX	$121.01	-13.08%	AU
Moderna, Inc. MRNA.US	$138.18	473.58%	US
Lonza Group AG LONN.SW	$754.32	6.50%	CH

Company

Stock price

Change 1y%

Country